Determining prescription durations based on the parametric waiting time distribution

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 12, 2016, Pages 1451-1459

  Støvring, Henrik ^a   Pottegård, Anton ^b,c   Hallas, Jesper ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

maximum likelihood; parametric modelling; pharmacoepidemiology; prescription durations; waiting time distribution

Indexed keywords

BENDROFLUMETHIAZIDE; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN; PRESCRIPTION DRUG;

ARTICLE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRESCRIPTION DURATION; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS; WAITING TIME DISTRIBUTION; ALGORITHM; COMPUTER SIMULATION; HUMAN; PROCEDURES; STATISTICAL MODEL; TIME FACTOR;

ALGORITHMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; PHARMACOEPIDEMIOLOGY; PRESCRIPTION DRUGS; TIME FACTORS;

EID: 84994795053     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4114     Document Type: Article

References (11)

1. Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997; 8: 666–70.
2. Pottegård A, Hallas J. Assigning exposure duration to single prescriptions by use of the waiting time distribution. Pharmacoepidemiol. Drug Saf. 2013; 22: 803–809. doi:10.1002/pds.3459.
3. Stovring H, Vach W. Estimation of prevalence and incidence based on occurrence of health-related events. Stat. Med. 2005; 24: 3139–54.
4. Wiley: Continuous Univariate Distributions, 1, 2nd Edition Norman L. Johnson, Samuel Kotz, N. Balakrishnan. Available at: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0471584959.html. Accessed July 5, 2016.
5. Zhao Y. Parametric inference from window censored renewal process data. 2006. Available at: https://etd.ohiolink.edu/rws_etd/document/get/osu1164678679/inline.
6. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan. Med. Bull. 1997; 44: 445–8.
7. StataCorp. Stata Statistical Software: Release 14. StataCorp LP: College Station, TX, 2015.
8. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol. Drug Saf. 1998; 7: 275–280.
9. Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J. Clin. Epidemiol. 2010; 63: 422–427. doi:10.1016/j.jclinepi.2009.07.001.
10. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 2005; 58: 323–337. doi:10.1016/j.jclinepi.2004.10.012.
11. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin. Pharmacol. Toxicol. 2006; 98: 260–265. doi:10.1111/j.1742-7843.2006.pto_257.x.